Recombinant Human CXC-Chemokine Receptor-4 in Melanophores Are Linked to Gi Protein: Seven Transmembrane Coreceptors for Human Immunodeficiency Virus Entry into Cells

Abstract

This article describes the transient expression of the CXC chemokine receptor-4 in Xenopuslaevis melanophores and the resulting functional assay for the endogenous ligand for this receptor stromal cell-derived factor (SDF)-1α. Specifically, it will be shown that SDF-1α produces increased light transmittance in transfected cells that is consistent with the activation of Gi protein. This stimulus pathway is further implicated by the abolition of this response after pretreatment of the cells with pertussis toxin, a known method for the inactivation of Giprotein. The fact that SDF-1α does not produce responses in nontransfected cells and that treatment of the cells with 12G5, an antibody specific for the CXC chemokine receptor-4, eliminates this response indicates that this ligand produces responses by activation of this receptor in these cells. The possible relevance to human immunodeficiency virus (HIV) entry into cells was explored by observing the effects of SDF-1α on HIV-mediated cell fusion. It was found that SDF-1α blocked cell-to-cell fusion (as has been previously reported) at concentrations 1200-fold greater than those required to produce Gi protein mediated responses. The implications of the functional assay to screening for new drugs to block HIV-mediated fusion is discussed.

Footnotes

  • Send reprint requests to: Terry Kenakin, Ph.D., Department of Receptor Biochemistry, Glaxo Wellcome Research and Development, 5 Moore Drive, Research Triangle Park, NC 27709.

  • Abbreviations:
    HIV-1
    human immunodeficiency virus type 1
    CXCRx
    CXC chemokine receptor, where xis the receptor number
    SDF
    stromal cell-derived factor
    BSA
    bovine serum albumin
    PCR
    polymerase chain reaction
    HEPES
    4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
    SDS
    sodium dodecyl sulfate
    ED50
    dose effective on 50% of the population
    • Received August 29, 1997.
    • Accepted October 29, 1997.
« Previous | Next Article »Table of Contents